TTR and cardiomyopathy: In a large population-based US health care cohort with exome sequencing data, we found that individuals with P/LP variants in TTR identified by genomic screening had significantly increased odds of heart disease (including heart failure, cardiomyopathy, and atrial fibrillation) on or after the age of 60 years.